Squamous Cell Carcinoma of Head and Neck

ASP-1929 + anti-PD-1 therapy in patients with locoregional/metastatic head and neck squamous cell carcinoma demonstrated an objective response rate of 29.4%. #HNSCC #hancsm | @MDAndersonNews @agillenw https://t.co/qUls97yI3r (@TargetedOnc)

Thanks @NIDCR @NIH for this #K99/R00 Pathway to Independence Award! Extremely grateful and equally excited to work with a team of incredible mentors @GPratx @JohnSunwooMD @Qle_stanford and collaborators across @StanfordMed @StanfordEng ! #HNSCC #Cancer #Organoids #Bioprinting (@SYAMANTAkHAN)

@CelSciCorp in continuing discussions w/ @FDAOncology regarding Multikine in SCCHN. $CVM preparing additional materials for next FDA meeting while concurrently pursuing EU, UK & Canada approval. CVM says🇨🇦approval could come as soon as '24. https://t.co/yrWqtbFvCf (@vanjohn10)

Healio spoke with @LouiseDaviesMD regarding study findings showing that a publicly available calculator effectively estimated survival among a cohort of patients with oral squamous cell carcinoma. https://t.co/J0b5YR6CN1 (@HemOncToday)

🔥frm IJSO press: CT Screening for Pulmonary Mets in HNSCC Large cohort study, utility of CT, cost saving over PETCT https://t.co/I3C2SJaGrB @drshreyashukla @ujjwalagarwalmd @drvaishricha @docdcruz @pankajch37 @VanitaNoronha @sarbani30 @DrArpitaSahu @DrVijayPatil11 @Kajari16 (@AMCancerImaging)

Data proving further, the need for long term outcomes analysis. HPV status isn't the only criteria for selecting treatment.@dnair78 @VinPaleri Surgery vs Chemoradiation Outcomes in Patients With T1-T2 Oropharyngeal Squamous Cell Carcinoma https://t.co/rUjumKhZpM (@drprathameshpai)

Congratulations to Dr. Tim Chan @GeneCollector, the 2023 @AHNSinfo John Conely lecturer, who gave a brilliant keynote reviewing his transformational work on tumor mutational burden and immunotherapy for HNSCC and other tumors. Bravo! (@rbryanbell)

@GeneCollector making HNSCC immunology simple and promising #AHNS2023 @AHNSinfo @RambamHCC (@SaeedSalmanMD)

This study not relevant anymore in second-line because shifting IO to first-line#first-line study efti+pembro coming to an end👊👊#chemo-free regimens welcome in HNSCC💥 (@WLybaert)

Tillykke med artiklen @Ruta51463637 @christian_roenn @HorsholtMorten @profOvergaard @j_grau_eriksen m.fl. 👏🏼 #HNSCC #DAHANCA 👏🏼 @oncaarhus (@onko_ouh)

The review does highlight the conundrum but the para on the DHANUSH seems like of an after note. Isnt showing results even wid use of 2d rt make it validatory? guess the best evidence for hpv-ve hnscc is doce @DrVijayPatil11 @Sarbani28178063 https://t.co/e1Za8aAs6h (@qburhan)

It’s crazy that HR 1.30 would be accepted as non-inferior in HNSCC. It’s equally crazy to me that dose-escalating NSCLC was shown very rigorously to have an HR of ~1.3 & people still do it because they remain convinced it MUST be better. 🤷🏼‍♂️ (@drmattmc)

Also this is not evidence based. When was another incidence of T4a/b HNSCC that we are comfortably omitting systemic therapy altogether? (@CJTsaiMDPhD)

Just released our comprehensive work about prognostic and predictive biomarkers in HNSCC. Special thanks to @ESMO_Open @myESMO for the opportunity and to @licitra_lisa, @drsalvoalfieri and @Simorota6 for the amazing team work. https://t.co/KQp5k8bbpT (@BubiSilvi)

✅ Nivolumab and Chemoradiation HNSCC: DEPEND Trial 📹 video https://t.co/9h1zNBtsGS #HNSCC #DependTrial #CancerResearch #ASCO23 @AriRosenbergMD @UChicago (@oncologytube)

Amazing panel discussing challenges and strategies of immunotherapy for #HNSCC from different perspectives w/Proff @DrHaddadRobert @JohnSunwooMD Danny Rischin, Nicole Schmitt and Ryuhei Okada @Ifhnos_official #IFHNOS23 (@elenacolomboMD)

Inspiring talk by @HSkinnerMDPhD at #IFHNOS23 on strategies for increasing radiosensitivity in #HNSCC @Ifhnos_official (@elenacolomboMD)

The second day of the Wolfsberg Meeting continues with the talk of Prof. Krause @KrauseProf, where she shared the clinical validation for similarity of Biomarkers for radiochemotherapy in patient Head and Neck Squamous Cell Carcinoma and in xenograft models. #OncoRay #RadOnc (@UKahya91)

I heard from colleagues during #ASCO23 that the recently published ⁦@ASCO⁩ guideline on immunotherapy in R/M HNSCC has been helpful in practice. @drlorenmell Here is the link to our podcast with @BrittanyEHarvey discussing the guideline. https://t.co/7JycmFeJqK (@YilmazMDPhD)

Metronomic chemo is criminally underutilized in USA - case in point SCCHN later lines .. (@RenoHemonc)

The #Duvvurilab is moving to the @nyugrossman ! We are hiring postdocs, students & technicians! Come study #SCCHN &translate science from!bench to bedside. We study oncogenesis, metabolism & resistance to immunotherapy From Seahorse 👉scRNA👉CUT&RUN @HainerLab @lucmorrisnyc (@duvvuri_md)

#Tumormicroenvironment #immunotherapy #HNSCC New Article Sharing 🌈Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancer 👉https://t.co/1bLNqZqLoq @hncalliance @JLGeigerMD @H_N_C_I_G @Grifondoro67 @RobertLMetcalf (@cdrjournal)

Really excited about these #asco23 results from @AriRosenbergMD @UCCancerCenter @UChicagoOHNS @UChicagoRadonc. #neoadjuvant #ChemoIO selection in #hnscc empowers better tolerance and encouraging outcomes. (@lab_pearson)

From 1:15pm CDT, Martin Forster (@uclh) & @MatthewGKrebs' reserch is being presented on the results from a phase II study of eftilagimod alpha + pembrolizumab in patients with metastatic head and neck squamous cell #Carcinoma: https://t.co/UDqNd2qe6K #ASCO23 (@CRUKresearch)

Excited to present our collaborative work w/ Drs. Zandberg, Whiteside, @RobertFerrisMD , Swartz on predictive value of exosome (ex) for response to I/O in HNSCC: High T-cell derived CD3+ ex, tumor-derived ex suppression/stimulation ratio a/w ⬆️ I/O efficacy. (Abstract 6042) (@ronanhsieh)

Hear @jdschoenfeld1 discuss which patients with #HNSCC might benefit from emerging IAP antagonists, as they are approved. #oncology #MedEd #CME #GetYourAnswersInCME https://t.co/2DOwbwunYA (@AnswersinCME)

Oral triple metronomic chemotherapy is effective in second line relapsed refractory HNSCC . Phase 3 RCT Congratulations @VanitaNoronha @ASCO @OncoAlert @rushabh1388 #asco23 @tmhmedoncalumni @ACTREC_TMC @cspramesh (@SuyogCancer)

Wondering whether the longer neoadjuvant portion (compared to other definitive IO CRT HNSCC trials) before we recklessly, electively irradiate the nodes gives time for CD8 T cell activation in the draining nodes. (@seanmmcbride)

I think we are all in agreement that TDLN is the key to neoadjuvant IO response in HNSCC… I just wonder if there is a deeper, more extensive LN potential beyond TDLN in these virally driven cancers? (@DrGopalIyer)

How do we explain this? @KaramLab @DrGopalIyer @seanmmcbride As simple as different biology? Data from CONTINUUM trial presented at #ASCO23 Results: - PFS improvement: 79% vs 86% - No OS diff - CRT given the same way as HNSCC RCTs Great discussion by Prof_Chan @CUHKMedicine (@DrMLChua)

⁦@HeadNeckMD⁩ presenting BCA101 and pembrolizumab combination data in r/m hnscc. (@YilmazMDPhD)

We’re grateful for the work & contributions of Dr. Glenn Hanna @HeadNeckMD presenting most recent & exciting data from Bicara’s Phase 1/1b study of our dose expansion cohort in front-line R/M #HNSCC at #ASCO2023 today. Tune into our #webinar for more: https://t.co/0FBZ1rnhwW (@BicaraTx)

Encouraging anti-tumor activity for patients w/metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGFβ inhibitor BCA101 w/pembrolizumab. Dose expansion results reported by @DanaFarber's Glenn Hanna, MD, (@HeadNeckMD) at #ASCO23. (@DanaFarberNews)

Very promising activity observed with BCA101 + pembro in p16 negative cps 1-19% 1st line R/M HNSCC. Exceptional presentation by @HeadNeckMD at #ASCO23 (@AhernandoCalvo)

India shining at @ASCO #ASCO2023 with practice changing studies @batraatulmd @aiims_newdelhi and Dr Rushabh Kothari (CRSF,a prominent cooperative oncology group in India ) @oncologician 1. Diclofenac cream for HFS 2- OMCT vs physician choice in recurrent met HNSCC 2nd line (@Prasshmehta)

@ASCO #ASCO2023 Practice changing studies from @batraatulmd @aiims_newdelhi Diclofenac cream for HFS Dr Rushabh Kothari (CRSF) @oncologician OMCT vs physician choice in recurrent met HNSCC 2nd line India making an impact on the world stage @PSKulkarni (@IJMPOofficial)

It was great to speak with @AriRosenbergMD at #ASCO23 on all things #HeadAndNeckCancer Stay tuned for more on https://t.co/ys1d8pDAKO 👀 #HNSCC @ASCO (@VJOncology)

Great work @JMuzaffarMD @HumairaSarfraz2 . Come see our poster Microbiome Metabolomics and Fasting in HNSCC 6/5/23. Poster 43. @NazliDizman @Daniel_J_George @DukeGUCancer @realKrupalP @montypal @LuisMezaco (@BariShahlaMD)

Association of molecular profiles of head and neck squamous cell carcinoma with heterogeneity across racial/ethnic groups in the United States [2023] Bhayani et al. #ASCO23 Abst e18036 https://t.co/qFTb4yHTWx #hncsm @RushCancer @TempusLabs (@mtmdphd)

Pt不耐なRM-SCCHNに対する1st line P2 ｲﾐﾌｨﾝｼﾞ+PTX+CBDCA n=64 CPS>20症例は37.3% mOS 18m(95%CI 11.9-NR) 24m OS rate 45% mPFS 7.0m CPS>20が多い気もするが、ｍOS 18ヶ月はかなり良い数字か #ASCO2023 https://t.co/aL27ab30Y1 (@Honekko_oncolo)

HPV Advances: In this video, Dr. @DrJaredWeiss discusses treatment options for patients who have SCCHN and high PD-L1. https://t.co/Nxj72SZxTh Thank you to our sponsors: Merck and Genentech. For more, please visit https://t.co/3VETMT8eM4. (@cancerGRACE)

Detecting Recurrent/Metastatic HPV+ SCCHN - HPV Advances https://t.co/vrBUT4o3Tm via @YouTube 2022 Program: HPV Advances: In this video, Dr. @DrJaredWeiss discusses how incurable head and neck cancer is generally found, and recent data on life expectancy. (@cancerGRACE)